Genentech, a major player in the pharmaceutical industry, is actively soliciting research to support its opposition to proposed reforms in Washington.
This initiative appears to be a strategic response to anticipated regulatory changes that could impact the industry.
The company is particularly interested in studies that underscore the advantages of existing practices within the pharmaceutical sector.